Fate Therapeutics Inc FATE:NASDAQ

Last Price$39.25NASDAQ Previous Close - Last Trade as of 4:00PM ET 9/18/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$39.30 (32)
Ask (Size)$39.70 (13)
Day Low / HighN/A - N/A
Volume2.6 M
  • Latest Stories
  • Commentary and Analysis
Insider Trends: Fate Therapeutics Insider Sale Interrupting 90-Day Buy Trend
4:03PM ET 9/16/2020 MT Newswires

Daniel D Shoemaker, Chief Scientific Officer, sold 25,000 shares of Fate Therapeutics (FATE) on Sep 14, 2020, for $907,540. Subsequent to the Form 4...

Fate Therapeutics Names New Finance Chief
8:38AM ET 8/19/2020 MT Newswires

Fate Therapeutics (FATE) said Wednesday Edward Dulac has been appointed as its new finance chief. Dulac most recently served as vice president in Celgene's...

Analyst Actions: Cantor Fitzgerald Lifts Fate Therapeutics PT to $40 From $32, Maintains Overweight Rating
11:08AM ET 8/13/2020 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $37. (MT Newswires covers equity, commodity and economic...

Fate Therapeutics Q2 Results Miss Expectations
4:29PM ET 8/05/2020 MT Newswires

Fate Therapeutics (FATE) on Wednesday reported a Q2 loss per diluted share of $0.35, narrower than the loss of $0.36 a year ago. Revenue increased to $5.5...

-- Earnings Flash (FATE) FATE THERAPEUTICS INC. Posts Q2 EPS $-0.35
4:13PM ET 8/05/2020 MT Newswires


Fate Therapeutics, Baylor College of Medicine Sign License Deal for Alloimmune Defense Receptors
9:07AM ET 7/14/2020 MT Newswires

Fate Therapeutics (FATE) said premarket Tuesday it signed an exclusive license deal with Baylor College of Medicine covering alloimmune defense receptors,...

Fate Therapeutics Wins FDA Clearance Of Investigational New Drug Application For Cancer Therapy FT819
8:15AM ET 7/09/2020 MT Newswires

Fate Therapeutics (FATE) said Thursday the US Food and Drug Administration has cleared the company's investigational new drug application for FT819, which...

Insider Makes Significant Stock buy in Fate Therapeutics (FATE) Shares Breaks neutral Trend of Last 90 Days
10:18PM ET 6/18/2020 MT Newswires

Significant insider buying activity was revealed in Fate Therapeutics shares in a form 4 document filed with the SEC today, showing -- Redmile Group Llc,...

Insider Trends: Insider Purchase Continues Fate Therapeutics Positive Trend
8:28PM ET 6/17/2020 MT Newswires

Redmile Group Llc, 10% Owner and Director, purchased 1,412,928 shares of Fate Therapeutics (FATE) on Jun 11, 2020, for $39,999,992. After the Form 4...

Analyst Actions: Oppenheimer Lifts Fate Therapeutics PT to $40 From $34 on FT596 Showing Early Signs of Activity, Maintains Outperform Rating
10:44AM ET 6/10/2020 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $36. Price: 33.99, Change: +1.27, Percent Change: +3.90...